Clinical Trial Update: Behavioural Activation Therapy and Esketamine for Resistant Depression [NA]

View source ↗

Summary

A clinical trial evaluating behavioural activation therapy in combination with esketamine for treatment-resistant depression and related mood disorders has been…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Major Depressive Disorder

Drugs mentioned

• SPRAVATO (ESKETAMINE HYDROCHLORIDE)

Snippet

Sponsor: The Royal's Institute of Mental Health Research | Conditions: Depressive Disorder, Treatment-Resistant, Depressive Disorder, Major | NA | Status: TERMINATED